The Cost of Care for People With Chronic Kidney Disease

Braden Manns, Brenda Hemmelgarn, Marcello Tonelli, Flora Au, Helen So, Rob Weaver, Amity E Quinn, Scott Klarenbach, for Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease, Braden Manns, Brenda Hemmelgarn, Marcello Tonelli, Flora Au, Helen So, Rob Weaver, Amity E Quinn, Scott Klarenbach, for Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease

Abstract

Background: As the adverse clinical outcomes common in patients with chronic kidney disease (CKD) can be prevented or delayed, information on the cost of care across the spectrum of CKD can inform investments in CKD care.

Objectives: To determine the cost of caring for patients with CKD who are not on dialysis or transplant at baseline.

Design: Population-based cohort study using administrative health data.

Setting: Alberta, Canada.

Patients: Cohort of 219 641 adults with CKD categorized by estimated glomerular filtration rate (eGFR) between April 1, 2012, and March 31, 2014, into Kidney Disease: Improving Global Outcomes (KDIGO) CKD categories, excluding patients on dialysis or transplant at baseline.

Measurements: The primary outcome was 1-year cumulative unadjusted health care costs, including the cost of drugs, physician visits, emergency department visits, outpatient procedures (including dialysis and other day medicine and surgery procedures), and hospitalizations for the year following each patient's index date.

Methods: Mean 1-year direct medical costs were estimated for the cohort as a whole and for patients in the different KDIGO CKD categories as defined at baseline. Costs were further categorized according to baseline demographic and clinical characteristics, and by type of care (ie, kidney care and cardiovascular care).

Results: In 219 641 adults with CKD, the mean unadjusted cumulative 1-year cost of care was Can$14 634 per patient (median = Can$3672; Q1 = Can$1496, Q3 = Can$10 221). Costs were higher for those with more comorbidity, those with lower eGFR, and those with more severe albuminuria. The cost of kidney and cardiovascular care was Can$230 (1.6% of total costs) and Can$720 (4.9% of total costs), respectively, for the cohort overall. These costs increased substantially for patients with lower eGFR, averaging Can$14 169 (32.3% of total costs) and Can$2395 (5.5% of total costs) for kidney and cardiovascular care, respectively, for people with eGFR<15 mL/min/1.73 m2 at baseline.

Limitations: We only have estimates of the cost of health care for people with CKD, and not the costs borne by patients or their families. As we have not included costs for people without CKD in this analysis, we are unable to assess the incremental costs associated with CKD.

Conclusions: We identified that patients with CKD, even when not on dialysis at baseline, had high health care costs (more than twice the cost per person in Canada in 2015), with a graded association between severity of CKD and costs. Our findings can inform current and future cost estimates across the spectrum of CKD, including an estimate of potential savings that might result from interventions that slow or prevent kidney disease.

Keywords: CKD (chronic kidney disease); health care costs; health economics.

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: This study is based in part on data provided by Alberta health and Alberta Health Services. The interpretation and conclusions contained herein are those of the researchers and do not necessarily represent the views of the Government of Alberta or Alberta Health Services. Neither the Government of Alberta nor Alberta Health or Alberta Health Services express any opinion in relation to this study.

Figures

Figure 1.
Figure 1.
Mean 1-year costs of care for patients across KDIGO chronic kidney disease categories, by category of cost. Note. KDIGO = Kidney Disease: Improving Global Outcomes; eGFR = estimated glomerular filtration rate; ED = emergency department. aeGFR<15 mL/min/1.73 m2 excludes those on dialysis at baseline. bNondialysis and non-ED costs represent ambulatory care costc other than ED cost and dialysis and nephrologist visit–related costs. cIncluding visits in ED, noninterventional services (ie, clinical assessments, diagnostic services such as imaging and treatment, and education), rehabilitation services and community-based services, as well as procedures such as day surgery.

References

    1. Arora P, Vasa P, Brenner D, Iglar K, McFarlane P, Morrison H, Badawi A. Prevalence estimates of chronic kidney disease in Canada: results of a nationally representative survey. CMAJ. 2013;185(9):E417-123.
    1. Manns B, Tonelli M, Culleton B, et al. ; and Alberta Kidney Disease Network. A cluster randomized trial of an enhanced eGFR prompt in chronic kidney disease. Clin J Am Soc Nephrol. 2012;7:565-572.
    1. Lee H, Manns B, Taub K, et al. Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access. Am J Kidney Dis. 2002;40(3):611-622.
    1. Beaudry A, Ferguson TW, Rigatto C, Tangri N, Dumanski S, Komenda P. Cost of dialysis therapy by modality in Manitoba. Clin J Am Soc Nephrol. 2018;13(8):1197-1203.
    1. Dialysis modalities for the treatment of end-stage kidney disease: a review. In: CADTH Report/Project in Briefs. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health, 2011.
    1. Canadian Institute for Health Information (CIHI). Treatment of End-Stage Organ Failure in Canada, Canadian Organ Replacement Register, 2005 to 2014. Ottawa, ON: Canadian Institute for Health Information, 2015.
    1. Interdisciplinary Chronic Disease Collaboration, Alberta Kidney Disease Network. Quality of care in early stage chronic kidney disease 2012-2013.Alberta, Canada: Alberta Health Services, 2015.
    1. Vupputuri S, Kimes TM, Calloway MO, et al. The economic burden of progressive chronic kidney disease among patients with type 2 diabetes. J Diabetes Complications. 2014;28(1):10-16.
    1. James MT, Quan H, Tonelli M, et al. ; and Alberta Kidney Disease Network. CKD and risk of hospitalization and death with pneumonia. Am J Kidney Dis. 2009;54:24-32.
    1. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1-50.
    1. Hemmelgarn BR, Clement F, Manns BJ, et al. Overview of the Alberta kidney disease network. BMC Nephrol. 2009;10:30.
    1. Johnson D, Jin Y, Truman C. Influence of aboriginal and socioeconomic status on birth outcome and maternal morbidity. J Obstet Gynaecol Can. 2002;24(8):633-640.
    1. Pohar SL, Johnson JA. Health care utilization and costs in Saskatchewan’s registered Indian population with diabetes. BMC Health Serv Res. 2007;7:126.
    1. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
    1. Statistics Canada. The Canadian consumer price index reference paper. Ottawa, ON: The Minister responsible for Statistics Canada, 2015.
    1. Statistics Canada. 2016. population by sex and age group table, 2016. . Accessed February 23, 2019.
    1. Klarenbach SW, Tonelli M, Chui B, Manns BJ. Economic evaluation of dialysis therapies. Nat Rev Nephrol. 2014;10:644-652.
    1. Eriksson JK, Neovius M, Jacobson SH, Elinder CG, Hylander B. Healthcare costs in chronic kidney disease and renal replacement therapy: a population-based cohort study in Sweden. BMJ Open. 2016;6(10):e012062.
    1. Kent S, Schlackow I, Lozano-Kuhne J, et al. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease. BMC Nephrol. 2015;16:65.
    1. Vekeman F, Yameogo ND, Lefebvre P, Bailey RA, McKenzie RS, Piech CT. Healthcare costs associated with nephrology care in pre-dialysis chronic kidney disease patients. J Med Econ. 2010;13(4):673-680.
    1. Wyld ML, Lee CM, Zhuo X, et al. Cost to government and society of chronic kidney disease stage 1-5: a national cohort study. Intern Med J. 2015;45(7):741-747.
    1. Baumeister SE, Boger CA, Kramer BK, et al. Effect of chronic kidney disease and comorbid conditions on health care costs: a 10-year observational study in a general population. Am J Nephrol. 2010;31(3):222-229.
    1. Smith DH, Gullion CM, Nichols G, Keith DS, Brown JB. Cost of medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population. J Am Soc Nephrol. 2004;15(5):1300-1306.
    1. Nichols GA, Vupputuri S, Lau H. Medical care costs associated with progression of diabetic nephropathy. Diabetes Care. 2011;34(11):2374-2378.
    1. Honeycutt AA, Segel JE, Zhuo X, Hoerger TJ, Imai K, Williams D. Medical costs of CKD in the Medicare population. J Am Soc Nephrol. 2013;24(9):1478-1483.
    1. Manns B, McKenzie SQ, Au F, Gignac PM, Geller LI; Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease (Can-SOLVE CKD) Network. the financial impact of advanced kidney disease on Canada pension plan and private disability insurance costs. Can J Kidney Health Dis. 2017;4:2054358117703986.
    1. Canadian Institute for Health Information (CIHI). National health expenditure trends, 1975 to 2016. Ottawa, ON: Canadian Institute for Health Information, 2016.
    1. Austin PC, Daly PA, Tu JV. A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario. Am Heart J. 2002;144(2):290-296.
    1. Lee DS, Donovan L, Austin PC, et al. Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research. Med Care. 2005;43(2):182-188.
    1. Kokotailo RA, Hill MD. Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10. Stroke. 2005;36(8):1776-1781.

Source: PubMed

3
Tilaa